BioVaxys Technology Corp. Closes Debt Settlement Transaction

Core Points - BioVaxys Technology Corp. has issued 1,792,387 common shares at a deemed value of $0.23 per share to settle an outstanding debt of $412,249 [1][2] Company Overview - BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company based in British Columbia, Canada, focused on developing novel immunotherapies using the DPX™ immune-educating technology platform and the HapTenix© tumor cell construct platform [4] - The company's clinical pipeline includes maveropepimut-S (MVP-S), which is in Phase IIB development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant Ovarian Cancer [4] - MVP-S targets survivin, a cancer antigen, and has shown clinical benefits and activation of a survivin-specific anti-tumor immune response [4] - BioVaxys is also developing other therapies, including DPX™+SurMAGE for dual-targeted immunotherapy, DPX™-RSV for Respiratory Syncytial Virus, and BVX-0918, a personalized immunotherapeutic vaccine for late-stage ovarian cancer [4] Securities Information - BioVaxys common shares are listed on the Canadian Securities Exchange (CSE) under the symbol "BIOV" and also trade on the Frankfurt Bourse and OTC Markets [5]